288 related articles for article (PubMed ID: 19538101)
21. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
Barchet TM; Amiji MM
Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More.
Costa LG; Garrick JM; Roquè PJ; Pellacani C
Oxid Med Cell Longev; 2016; 2016():2986796. PubMed ID: 26904161
[TBL] [Abstract][Full Text] [Related]
23. Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller KM; Carty ML; Reinebrant HE; Wixey JA
J Neurosci Res; 2009 Feb; 87(3):599-608. PubMed ID: 18831005
[TBL] [Abstract][Full Text] [Related]
24. Correction of the high blood viscosity syndrome by a mixture of Diquertin and Ascorbic Acid in vitro and in vivo.
Plotnikov MB; Aliev OI; Maslov MJ; Vasiliev AS; Tjukavkina NA
Phytother Res; 2003 Mar; 17(3):276-8. PubMed ID: 12672161
[TBL] [Abstract][Full Text] [Related]
25. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.
Stone TW; Ceruti S; Abbracchio MP
Handb Exp Pharmacol; 2009; (193):535-87. PubMed ID: 19639293
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis.
Ishizawa K; Yoshizumi M; Kawai Y; Terao J; Kihira Y; Ikeda Y; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T
J Pharmacol Sci; 2011; 115(4):466-70. PubMed ID: 21436601
[TBL] [Abstract][Full Text] [Related]
27. Glial metabolism of quercetin reduces its neurotoxic potential.
Vafeiadou K; Vauzour D; Rodriguez-Mateos A; Whiteman M; Williams RJ; Spencer JP
Arch Biochem Biophys; 2008 Oct; 478(2):195-200. PubMed ID: 18675775
[TBL] [Abstract][Full Text] [Related]
28. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
Ludolph AC; Drory VE
J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
[No Abstract] [Full Text] [Related]
29. Linkage between immunomodulation, neuroprotection and neurogenesis.
Aharoni R; Arnon R
Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
[TBL] [Abstract][Full Text] [Related]
30. Nicaraven Chugai.
Leker RR
Curr Opin Investig Drugs; 2003 Jan; 4(1):83-90. PubMed ID: 12625035
[TBL] [Abstract][Full Text] [Related]
31. Ingredients for functional drinks in neurodegenerative diseases: a review.
Zafrilla P; Morillas JM; Rubio-Perez JM; Cantos Villar E
Nat Prod Commun; 2009 May; 4(5):719-40. PubMed ID: 19445320
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases.
Alvarez-Arellano L; Salazar-García M; Corona JC
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260783
[TBL] [Abstract][Full Text] [Related]
33. The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms.
Chiang MC; Tsai TY; Wang CJ
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047299
[TBL] [Abstract][Full Text] [Related]
34. Anxiety and cognitive effects of quercetin liposomes in rats.
Priprem A; Watanatorn J; Sutthiparinyanont S; Phachonpai W; Muchimapura S
Nanomedicine; 2008 Mar; 4(1):70-8. PubMed ID: 18249157
[TBL] [Abstract][Full Text] [Related]
35. Near-Infrared Radiation-Assisted Drug Delivery Nanoplatform to Realize Blood-Brain Barrier Crossing and Protection for Parkinsonian Therapy.
Liu Y; Hong H; Xue J; Luo J; Liu Q; Chen X; Pan Y; Zhou J; Liu Z; Chen T
ACS Appl Mater Interfaces; 2021 Aug; 13(31):37746-37760. PubMed ID: 34318658
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of glycosylated quercetin to enhance neuroprotective effects on cerebral ischemia-reperfusion.
Wang S; Chen Y; Xia C; Yang C; Chen J; Hai L; Wu Y; Yang Z
Bioorg Med Chem; 2022 Nov; 73():117008. PubMed ID: 36126445
[TBL] [Abstract][Full Text] [Related]
37. Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis.
Karuppagounder V; Arumugam S; Thandavarayan RA; Sreedhar R; Giridharan VV; Watanabe K
Drug Discov Today; 2016 Apr; 21(4):632-9. PubMed ID: 26905599
[TBL] [Abstract][Full Text] [Related]
38. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
Kraemer B; Schellenberg GD
Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
[No Abstract] [Full Text] [Related]
39. TCP-FA4: a derivative of tranylcypromine showing improved blood-brain permeability.
Desino KE; Pignatello R; Guccione S; Basile L; Ansar S; Michaelis ML; Ramsay RR; Audus KL
Biochem Pharmacol; 2009 Dec; 78(11):1412-7. PubMed ID: 19679106
[TBL] [Abstract][Full Text] [Related]
40. Progesterone and progestins: neuroprotection and myelin repair.
Schumacher M; Sitruk-Ware R; De Nicola AF
Curr Opin Pharmacol; 2008 Dec; 8(6):740-6. PubMed ID: 18929681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
